Elad Sharon, MD, MPH
eladsharonmd.bsky.social
Elad Sharon, MD, MPH
@eladsharonmd.bsky.social
#MedicalOncologist @DanaFarber posting on #immunotherapy, #drugdevelopment, #irAEs & #HealthEcon. Formerly @theNCI & #CancerMoonshot Adult ImmunoTx Co-Chair
Watching the opening session for the #FriendsOfCancerResearch Annual Meeting! First up: seamless trial designs for rare cancer drug development! You can watch live and online: secure-web.cisco.com/1-aSs6clrewX...
November 4, 2025 at 3:20 PM
Excited to be speaking on November 4th Friends of Cancer Research annual meeting (#FriendsAM25)! I will be speaking on #ContributionOfEffect (#COE) You can still register online: secure-web.cisco.com/1-aSs6clrewX...
November 4, 2025 at 3:51 AM
Reposted by Elad Sharon, MD, MPH
Our 2025 ACI series concluded with sessions at ACR Convergence (Oct. 23) and APSHO's JADPRO (Oct. 27). Thank you everyone who made this series a roaring success! Missed a program? Access enduring materials: https://www.sitcancer.org/edu/aci

Jeffrey Sparks MD MMSc, Elad Sharon, MD, MPH
October 30, 2025 at 5:01 PM
Reposted by Elad Sharon, MD, MPH
Measles is back

Whooping cough is back

Now, diphtheria is staging a return with large outbreaks now in Somalia, Sudan, Yemen and Chad — countries with civil wars or large populations of refugees where vaccination coverage is low...

www.nytimes.com/2025/10/27/h... @stephanienolen.bsky.social
Diphtheria, a Once Vanquished Killer of Children, Is Resurgent
www.nytimes.com
October 27, 2025 at 11:00 AM
Reposted by Elad Sharon, MD, MPH
@ptarantinomd.bsky.social explores safety optimization of the next frontier of antibody-drug conjugate development. #ESMO25
October 19, 2025 at 7:19 AM
Reposted by Elad Sharon, MD, MPH
Dr. @pashtoonkasi discussed precision therapy in GI cancer, young CRC is mostly rectal and left-sided, high Her2 in gall bladder cancer, RAS testing on tissue often isn’t back in 2 weeks, liquid biopsy picks up heterogeneity, fusions, resistance mechs, at 2025 @WIN_Consortium Symposium.
October 6, 2025 at 12:32 AM
Reposted by Elad Sharon, MD, MPH
NRG-LU005 Trial at the ASTRO 67th Annual Meeting: Atezolizumab and BID Radiotherapy in Limited-Stage SCLC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NRG-LU005 #ASTRO25 #SCLC
NRG-LU005 Trial QOL Results at ASTRO 67th Annual Meeting
At ASTRO 67, the NRG-LU005 trial reported improved long-term quality of life with atezolizumab and twice-daily radiotherapy in limited-stage SCLC.
oncodaily.com
October 5, 2025 at 6:55 PM
Reposted by Elad Sharon, MD, MPH
What an amazing assay.

DAF-seq, the evolution of Fiber-seq from the Andrew Stergachis group, using the @pacbio.bsky.social platform:
www.biorxiv.org/content/10.1...

This will revolutionise our understanding of transcriptional regulation and functional non-coding variants.
Deaminase-assisted single-molecule and single-cell chromatin fiber sequencing
Gene regulation is mediated by the co-occupancy of numerous proteins along individual chromatin fibers. However, our tools for deeply profiling how proteins co-occupy individual fibers, especially at ...
www.biorxiv.org
October 4, 2025 at 12:06 PM
Reposted by Elad Sharon, MD, MPH
Inflammation is a key driver of the pathophysiology of cardiometabolic disorders #obesity #T2D and new metabolic medicines based on GLP-1 action exert their magic in part by reducing inflammation. A new review from Professor Donath summarizes the field www.sciencedirect.com/science/arti...?
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Obesity and its related disorders, including type 2 diabetes and liver, kidney, and cardiovascular diseases, are now recognized as chronic inflammator…
www.sciencedirect.com
October 3, 2025 at 3:23 PM
Reposted by Elad Sharon, MD, MPH
The Paris Summit of Synthetic Biology Centers, organized by @riceuniversity.bsky.social brought together global leaders of SynBio centers, biofoundries, and consortia to work out how to combine forces, grow expertise, fund discovery, and ensure ethical progress.
A productive 2 days in Paris!
September 30, 2025 at 6:40 PM
Reposted by Elad Sharon, MD, MPH
Olfactory dysfunction is common following SARS-CoV-2 infection, and can be detected on testing even in some who are unaware of having it/ don't report it (occult hyposmia)

(US RECOVER study sample)

#LongCovid

jamanetwork.com/journals/jam...
Olfactory Dysfunction After SARS-CoV-2
This cohort study examines the presence, severity, and patterns of olfactory dysfunction in US adults with and without prior SARS-CoV-2 infection.
jamanetwork.com
September 27, 2025 at 6:18 PM
Reposted by Elad Sharon, MD, MPH
Join us in downtown Washington, DC next Saturday October 4th for the DC Lung Cancer Conference, an IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25

Register today at medstarhealth.org/dclung25
September 26, 2025 at 2:26 PM
Reposted by Elad Sharon, MD, MPH
Thanks to all who made our Chicago group meeting a success! It went by too quickly, but it’s always refreshing to see our #SWOGonc community in person. We're grateful for our donors 🙏 And for those who picked up some new @swog.org swag, we’re excited to see where you’ll be spotted wearing it!
September 24, 2025 at 5:07 PM
Reposted by Elad Sharon, MD, MPH
‘One jab will do the job’: Pakistan begins rollout of HPV vaccine to millions of girls
‘One jab will do the job’: Pakistan begins rollout of HPV vaccine to millions of girls
Despite vaccination hesitancy, the end may be in sight for cervical cancer, which kills 64% of women with the disease
www.theguardian.com
September 15, 2025 at 12:36 PM
Reposted by Elad Sharon, MD, MPH
Partitioning obesity by genomics, proteomics and health outcomes from >450,000 UK Biobank
@naturemedicine.bsky.social

—A protective subtype vs cardiometabolic diseases (GRS BFP) and
—A risk subtype for these diseases (GRS uncoupling)
GRS-genomic risk score
nature.com/articles/s41...
September 12, 2025 at 5:51 PM
Reposted by Elad Sharon, MD, MPH
1/ Thrilled to share that my main PhD article has just been published in Nature Human Behaviour! 🎉

👉 “A randomised controlled trial on the effect of administrative burden and information costs on social inequalities in early childcare access in France” rdcu.be/eFAEA
A randomized controlled trial on the effect of administrative burden and information costs on social inequalities in early childcare access in France
Nature Human Behaviour - This RCT finds that providing information and support to target cognitive and behavioural barriers eliminates early childcare application gaps for low-income and immigrant...
rdcu.be
September 11, 2025 at 10:37 AM